Evidence map›Paper›PMID 41776051›Full record

ArticleOncogene2026

GITR activation potentiates anti-tumor immunity of tumor-infiltrating lymphocytes expanded from glioblastoma by rescuing exhaustion.

Jiayi Zhou, Yinggui Yang, Ran Ye, Jiani Lin, Huiyi Feng, Xiaojuan Pei, Mingzhen Li, Jiangfan Peng, Xinzhi Yang, Peter Yat Ming Woo and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jiayi Zhou *Department of Neurosurgery, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Yinggui Yang *Department of Neurosurgery, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Ran Ye *Department of Neurosurgery, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Jiani LinDepartment of Neurosurgery, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Huiyi FengDepartment of Oncology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Xiaojuan PeiDepartment of Pathology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Mingzhen LiDepartment of Pathology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Jiangfan PengDepartment of Neurosurgery, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China.
Xinzhi YangDepartment of Neurosurgery, Shenzhen Yantian District People's Hospital, Shenzhen, Guangdong, China.
Peter Yat Ming WooDepartment of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.ORCID http://orcid.org/0000-0002-7345-7904
Danny Tat Ming ChanDepartment of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Penghui ZhouState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.ORCID http://orcid.org/0000-0003-0519-461X
Jie MaoDepartment of Neurosurgery, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, China. myw921@yahoo.com.ORCID http://orcid.org/0000-0001-6082-9732
Zhuohao LiuDepartment of Neurosurgery, The Clinical Innovation & Research Centre, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China. shawnhz@smu.edu.cn.ORCID http://orcid.org/0000-0003-2487-3140
Dinglan WuDepartment of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. dlwu@surgery.cuhk.edu.hk.ORCID http://orcid.org/0000-0002-5057-9626

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82273341National Natural Science Foundation of China (National Science Foundation of China) 82372890Shenzhen Science and Technology Innovation Commission JCYJ20240813145316022
6 · The paper itself

Abstract

Autologous tumor-infiltrating lymphocyte (TIL) therapy holds transformative potential for solid tumors, yet its efficacy in glioblastoma remains limited by T cell exhaustion and immunosuppression. In the current study, we optimized an effective and reliable method for in vitro expansion of TILs from glioblastoma lesions and assessed their tumor-killing capacity both in vitro and in vivo. Single-cell RNA sequencing (scRNA-seq) of expanded TILs uncovered their heterogeneity and identified a cytotoxic tissue-resident memory (TRM) CD8

Indexed as

Brain NeoplasmsGlioblastomaGlucocorticoid-Induced TNFR-Related ProteinLymphocytes, Tumor-InfiltratingAnimalsCD8-Positive T-LymphocytesCell Line, TumorHumansLymphocyte ActivationMiceT-Cell ExhaustionT-Lymphocytes, RegulatoryGlucocorticoid-Induced TNFR-Related ProteinTNFRSF18 protein, human

Identifiers

PMID41776051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.